News

The trial met its primary endpoint of time from randomization to first clinical fracture (HR=0.5, 95 percent CI 0.39-0.65, p<0.0001). The observed 50 percent reduction in fractures between

The drug development and license agreement between Transposagen and Janssen, which was announced in November of 2014, has been transferred to Poseida. The three-year drug development partnership and

Researchers from both the parties will initially focus on canine malignant melanoma, or skin cancer, and test Nuovo’s new anti-cancer peptide drug MMX for its ability to treat

These data will be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting on June 1 in Chicago. Veliparib is an investigational oral poly (adenosine diphosphate

The companies will conduct clinical trials to evaluate the combination of Dynavax’s investigational toll-like receptor 9 (TLR9) agonist SD-101, with Merck’s anti-PD-1 therapy Keytruda (pembrolizumab) and its investigational

The Israeli company was first to file, making the product eligible for 180 days of market exclusivity. Risedronate sodium tablets, USP are the second approved product indicated to

The agency has granted priority review for this sBLA and is expected to respond by 30 September. The new application is based on data from CheckMate -069, the

As part of the transaction, Actavis will pay Auden £306m in cash and two-year royalty on a percentage of gross profits of one of Auden Mckenzie’s products. Actavis

Around 160 men aged 18 to 64 with sexual dysfunction related to secondary hypogonadism, or low levels of testosterone will be included in the randomized, double-blind, placebo-controlled, parallel